Patents Assigned to Asterias Biotherapeutics, Inc.
-
Patent number: 11920155Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.Type: GrantFiled: March 30, 2017Date of Patent: March 5, 2024Assignee: ASTERIAS BIOTHERAPEUTICS, INC.Inventors: Erik Michael Whiteley, Uzma Shoukat-Mumtaz, Rashi Srivastava, Nathan Charles Manley, Casey Christopher Case
-
Patent number: 11603518Abstract: Methods for differentiating human pluripotent stem cells to dorsal neuroectoderm progenitors and further to glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK/ERK signaling are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs in the absence of the ventralizing morphogen SHH or a SHH signaling activator. The methods of the present disclosure reproducibly produce dorsal neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.Type: GrantFiled: January 23, 2020Date of Patent: March 14, 2023Assignee: ASTERIAS BIOTHERAPEUTICS, INC.Inventors: Kento Onishi, Nathan C. Manley, Craig R. Halberstadt, Erik M. Whiteley
-
Patent number: 11123374Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells. Provided herein are a population of oligodendrocyte progenitor cells (OPCs) derived from pluripotent stem cells, methods of generating the same for use in the treatment of acute spinal cord injury and other conditions affecting the CNS, and containers including the population of OPCs.Type: GrantFiled: May 10, 2019Date of Patent: September 21, 2021Assignee: Asterias Biotherapeutics, Inc.Inventors: Edward D. Wirth, III, Jane S. Lebkowski, Nathan C. Manley
-
Publication number: 20210189335Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.Type: ApplicationFiled: March 30, 2017Publication date: June 24, 2021Applicant: Asterias Biotherapeutics, Inc.Inventors: Erik Michael WHITELEY, Uzma SHOUKAT-MUMTAZ, Rashi SRIVASTAVA, Nathan Charles MANLEY, Casey Christopher CASE
-
Publication number: 20200399592Abstract: This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.Type: ApplicationFiled: April 29, 2020Publication date: December 24, 2020Applicant: Asterias Biotherapeutics, Inc.Inventors: Ramkumar Mandalam, Yan Li, Isabelle Nadeau-Demers
-
Publication number: 20200231932Abstract: Methods for differentiating human pluripotent stem cells to dorsal neuroectoderm progenitors and further to glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK/ERK signaling are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs in the absence of the ventralizing morphogen SHH or a SHH signaling activator. The methods of the present disclosure reproducibly produce dorsal neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.Type: ApplicationFiled: January 23, 2020Publication date: July 23, 2020Applicant: Asterias Biotherapeutics, Inc.Inventors: Kento Onishi, Nathan C. Manley, Craig R. Halberstadt, Erik M. Whiteley
-
Patent number: 10676714Abstract: This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.Type: GrantFiled: February 12, 2018Date of Patent: June 9, 2020Assignee: Asterias Biotherapeutics, Inc.Inventors: Ramkumar Mandalam, Yan Li, Isabelle Nadeau-Demers
-
Publication number: 20190262405Abstract: Methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury are disclosed.Type: ApplicationFiled: September 14, 2017Publication date: August 29, 2019Applicant: Asterias Biotherapeutics, Inc.Inventors: Edward D. Wirth, III, Jane S. Lebkowski
-
Patent number: 10351821Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: October 16, 2017Date of Patent: July 16, 2019Assignee: Asterias Biotherapeutics Inc.Inventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 10344262Abstract: The invention provides methods of differentiating primate pluripotent stem cells into cells of hematopoietic lineage. The invention further provides hematopoietic lineage cells differentiated from primate pluripotent stem cells, as well as methods of using the same and kits comprising the same.Type: GrantFiled: February 6, 2017Date of Patent: July 9, 2019Assignee: Asterias Biotherapeutics, Inc.Inventors: Suyi Tseng, Anish Sen Majumdar, Kevin Nishimoto, Anita Reddy, Jane S. Lebkowski
-
Patent number: 10286009Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells.Type: GrantFiled: May 16, 2016Date of Patent: May 14, 2019Assignee: Asterias Biotherapeutics, Inc.Inventors: Edward D. Wirth, III, Jane S. Lebkowski
-
Patent number: 10221390Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.Type: GrantFiled: March 7, 2017Date of Patent: March 5, 2019Assignee: Asterias Biotherapeutics, Inc.Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
-
Patent number: 10059939Abstract: This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.Type: GrantFiled: December 12, 2011Date of Patent: August 28, 2018Assignee: Asterias Biotherapeutics, Inc.Inventors: Ramkumar Mandalam, Chunhui Xu, Joseph D. Gold, Melissa K. Carpenter
-
Publication number: 20180236004Abstract: In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In various embodiments, the methods involve administering stem cell-derived oligodendrocyte progenitor cells into or directly adjacent to the infarct core in the brain of the subject.Type: ApplicationFiled: August 15, 2016Publication date: August 23, 2018Applicants: Asterias Biotherapeutics, Inc., The Regents of The University of CaliforniaInventors: Edward D. Wirth, III, Stanley T. Carmichael, Irene Lorenzo Llorente, Nathan C. Manley
-
Patent number: 9803174Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: July 25, 2012Date of Patent: October 31, 2017Assignee: Asterias Biotherapeutics, Inc.Inventor: Melissa K. Carpenter
-
Patent number: 9790466Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: July 30, 2012Date of Patent: October 17, 2017Assignee: Asterias Biotherapeutics, Inc.Inventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 9745550Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.Type: GrantFiled: January 25, 2016Date of Patent: August 29, 2017Assignee: Asterias Biotherapeutics, Inc.Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
-
Patent number: 9587223Abstract: This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.Type: GrantFiled: August 27, 2013Date of Patent: March 7, 2017Assignee: Asterias Biotherapeutics, Inc.Inventors: Ramkumar Mandalam, Saadia Faouzi, Isabelle Nadeau, Kristina Pfendler-Bonham, Namitha Rao, Melissa K. Carpenter, Lakshmi Rambhatla, Choy-Pik Chiu
-
Patent number: 9243229Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.Type: GrantFiled: September 17, 2013Date of Patent: January 26, 2016Assignee: Asterias Biotherapeutics, Inc.Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
-
Patent number: 9238794Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.Type: GrantFiled: July 19, 2013Date of Patent: January 19, 2016Assignee: Asterias Biotherapeutics, Inc.Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger